Designing antifilarial drug trials using clinical trial simulators

• Published in: Nature communications 2020-06, Vol.11 (1), p.2685-11, Article 2685
• Main Authors: Walker, Martin, Hamley, Jonathan I. D., Milton, Philip, Monnot, Frédéric, Pedrique, Belén, Basáñez, Maria-Gloria
• Format: Article
• Language: English
• Subjects: 692/308; 692/699; Clinical Trial Protocols as Topic; Clinical trials; Clinical Trials as Topic - methods; Clinical Trials as Topic - statistics & numerical data; Computer Simulation; Design; Disease hot spots; Drug development; Drug Evaluation - methods; Drug Evaluation - statistics & numerical data; Drugs; Elephantiasis, Filarial - drug therapy; Filariasis; Filaricides - therapeutic use; Humanities and Social Sciences; Humans; Ivermectin - therapeutic use; Models, Biological; multidisciplinary; Onchocerciasis; Onchocerciasis - drug therapy; Onchocerciasis - parasitology; Onchocerciasis - transmission; Patients; Progeny; Science; Science (multidisciplinary); Simulators; Tropical diseases; Vector-borne diseases
• ISSN: 2041-1723; 2041-1723
• DOI: 10.1038/s41467-020-16442-y

Lymphatic filariasis and onchocerciasis are neglected tropical diseases (NTDs) targeted for elimination by mass (antifilarial) drug administration. These drugs are predominantly active against the microfilarial progeny of adult worms. New drugs or combinations are needed to improve patient therapy and to enhance the effectiveness of interventions in persistent hotspots of transmission. Several therapies and regimens are currently in (pre-)clinical testing. Clinical trial simulators (CTSs) project patient outcomes to inform the design of clinical trials but have not been widely applied to NTDs, where their resource-saving payoffs could be highly beneficial. We demonstrate the utility of CTSs using our individual-based onchocerciasis transmission model (EPIONCHO-IBM) that projects trial outcomes of a hypothetical macrofilaricidal drug. We identify key design decisions that influence the power of clinical trials, including participant eligibility criteria and post-treatment follow-up times for measuring infection indicators. We discuss how CTSs help to inform target product profiles. Drugs for filariases are under development and clinical trial simulators could help to inform the design of clinical trials. Here, Walker et al. use an individual-based onchocerciasis transmission model to project trial outcomes of a hypothetical macrofilaricidal drug, resolving key design choices.